BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30735328)

  • 1. [Allele-specific polymerase chain reaction and electrophoretic detection in the detection algorithm clinically significant somatic mutations in the gene of calreticulin (calr).].
    Gorbenko AS; Stolyar MA; Olkhovskiy IA; Abdullaev AO; Sudarikov AB; Dunaeva EA; Mironov KO; Shipulin GA
    Klin Lab Diagn; 2018; 63(9):588-592. PubMed ID: 30735328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformation sensitive gel electrophoresis for the detection of calreticulin mutations in BCR-ABL1-negative myeloproliferative neoplasms.
    Zakaria NA; Rosle NA; Siti Asmaa MJ; Aziee S; Haiyuni MY; Samat NA; Husin A; Hassan R; Ramli M; Mohamed Yusoff S; Ibrahim IK; Al-Jamal HAN; Johan MF
    Int J Lab Hematol; 2021 Dec; 43(6):1451-1457. PubMed ID: 34125992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAPID LOW-COST DETECTION OF TYPE 2CALR MUTATION BY ALLELE-SPECIFIC RT-PCR FOR DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS.
    Dybkov MV; Zavelevich MP; Gluzman DF; Telegeev GD
    Exp Oncol; 2022 May; 44(1):83-86. PubMed ID: 35548965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
    Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
    BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
    Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
    Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms.
    Mehrotra M; Luthra R; Singh RR; Barkoh BA; Galbincea J; Mehta P; Goswami RS; Jabbar KJ; Loghavi S; Medeiros LJ; Verstovsek S; Patel KP
    Am J Clin Pathol; 2015 Nov; 144(5):746-55. PubMed ID: 26486739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis.
    Jeong JH; Lee HT; Seo JY; Seo YH; Kim KH; Kim MJ; Lee JH; Park J; Hong JS; Park PW; Ahn JY
    Ann Lab Med; 2016 Jul; 36(4):291-9. PubMed ID: 27139600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms.
    Yao QM; Zhou J; Gale RP; Li JL; Li LD; Li N; Chen SS; Ruan GR
    Hematology; 2015 Oct; 20(9):517-22. PubMed ID: 25860380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of CALR mutation testing for clinical diagnosis.
    Maier CL; Fisher KE; Jones HH; Hill CE; Mann KP; Zhang L
    Am J Clin Pathol; 2015 Nov; 144(5):738-45. PubMed ID: 26486738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrosequencing-based quantitative measurement of CALR mutation allele burdens and their clinical implications in patients with myeloproliferative neoplasms.
    Oh Y; Song IC; Kim J; Kwon GC; Koo SH; Kim SY
    Clin Chim Acta; 2018 Aug; 483():183-191. PubMed ID: 29727699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel assay to detect calreticulin mutations in myeloproliferative neoplasms.
    Rosso V; Petiti J; Bracco E; Pedrola R; Carnuccio F; Signorino E; Carturan S; Calabrese C; Bot-Sartor G; Ronconi M; Serra A; Saglio G; Frassoni F; Cilloni D
    Oncotarget; 2017 Jan; 8(4):6399-6405. PubMed ID: 28031530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR.
    Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM
    Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous detection of JAK2, CALR, and MPL mutations and quantitation of JAK2 V617F allele burden in myeloproliferative neoplasms using the quenching probe-Tm method in i-densy IS-5320.
    Arai K; Sakaguchi M; Yui S; Kitano T; Miyata M; Yogosawa M; Nakayama K; Tajika K; Usuki K; Kuroda J; Uoshima N; Kobayashi Y; Uchiyama H; Kubota Y; Kimura S; Mori S; Hirai M; Wakita S; Yamaguchi H
    Int J Lab Hematol; 2022 Dec; 44(6):1102-1110. PubMed ID: 36039795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance].
    Tang Q; Zhang XW; Xia L; Jiang NK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):151-156. PubMed ID: 28245393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.
    Grinsztejn E; Percy MJ; McClenaghan D; Quintana M; Cuthbert RJ; McMullin MF
    Int J Lab Hematol; 2016 Feb; 38(1):102-6. PubMed ID: 26555437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
    Ha JS; Kim YK
    Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion.
    Smaili W; Doubaj Y; Laarabi FZ; Lyahyai J; Kerbout M; Mikdame M; Sefiani A
    Curr Res Transl Med; 2017; 65(1):15-19. PubMed ID: 28340692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
    Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
    Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2, CALR, and MPL Mutations in Egyptian Patients With Classic Philadelphia-negative Myeloproliferative Neoplasms.
    Soliman EA; El-Ghlban S; El-Aziz SA; Abdelaleem A; Shamaa S; Abdel-Ghaffar H
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e645-e651. PubMed ID: 32591258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.